Fairmount Funds Management, Director: Viridian Therapeutics, Inc.\DE VRDN Buy · Filed 24/01/24

Trade details

Type: Insider buy
Amount: $9,999,990
Shares · price: 476,190 sh · $21.00 a share
Held after: 1,839,954 sh
Stock: Viridian Therapeutics, Inc.\DE VRDN
Person: Fairmount Funds ManagementDirector
Trade date: 24/01/22
Filed: 24/01/24
Days to filing: 2 days

First buy since 2023

Insiders buying this week: 5 insiders
Holding change: +34.9%

Viridian Therapeutics, Inc.\DE trades, last 26 weeks

What else happened in Viridian Therapeutics, Inc.\DE around then

Filed or reported within 30 days of the trade day · 23/12/23~24/02/21

Fairmount Funds Management's recent trades

Fairmount Funds ManagementDirector, 10% Stockholder
Planned saleOruka Therapeutics
Planned sale
Oruka Therapeutics
ORKA
$300M
3,553,410 sh
$300M
Filed 07/01
Traded 07/01
Fairmount Funds ManagementDirector
Planned saleSpyre Therapeutics
Planned sale
Spyre Therapeutics
SYRE
$399.7M
4,684,781 sh
$399.7M
Filed 06/23
Traded 06/23
Fairmount Funds ManagementDirector
SellSpyre Therapeutics
Sell
Spyre Therapeutics
SYRE
$399.7M
4,684,781 sh
$399.7M
Filed 06/23
Traded 06/23
Fairmount Funds ManagementDirector
BuyViridian Therapeutics, Inc.\DE
Buy
Viridian Therapeutics, Inc.\DE
VRDN
$20M
1,176,470 sh
$20M
Filed 05/13
Traded 05/11
Fairmount Funds ManagementDirector
BuyZenas BioPharma
Buy
Zenas BioPharma
ZBIO
$3M
150,000 sh
$3M
Filed 04/01
Traded 03/31